Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Study of Ocular Side Effects in Subjects with Glioblastoma

Clinical Trial Title: 
A study for management of ocular side effects in subjects with glioblastoma receiving depatuxizumab mafodotin.
Clinical Trial Protocol ID: 
17120604
Clinical Trial Investigator Name: 
Joo Yeon Nam, MD
Clinical Trial Protocol Description: 

The main purpose of this study is to improve treatment of ocular (eye) side effects that result from depatuxizumab mafodotin (Depatux-M) use in subjects with glioblastoma (GBM).

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have newly diagnosed glioblastoma (GBM) histologically proven, World Health Organization (WHO) grade IV GBM or WHO grade IV gliosarcoma.
  • Demonstrate epidermal growth factor receptor (EGFR) amplification.
  • Have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.

You will be excluded from the study if any of the following criteria apply to you:

  • Have been newly diagnosed with GBM and have received prior chemotherapy or radiotherapy for cancer of the head and neck region; have received prior treatment with Gliadel wafers or any other intratumoral or intracavitary treatment.
  • Have hypersensitivity to any component of TMZ or dacarbazine.
  • Have received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy) within 5 years of Study Day 1.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Brain Tumors
Contact Phone: 
(312) 942-8729
Contact Name: 
Praneeth Chebrolu